You are right if it's for one IP with IMU's market potential as that's when BP will usually show interest as efficacy will be seen end of Ph2 but IMU has 3 of these IP but more importantly with the potential to expand into other blood and cancer market with VAXINIA and Azer-Cel already demonstrating efficacy, that's why there's plan for registrational clinical trial.
But I see your game as a closet RAC holder......
IMU Price at posting:
4.1¢ Sentiment: None Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)